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Sensitization to Saccharomyces cerevisiae has been associated with many conditions1,2 including atopic
dermatitis.3
Many vaccines including Hepatitis B vaccines are manufactured using  Saccharomyces cerevisiae 
(baker’s yeast).4–6
Wiedermann et al.7 anticipated that the large yeast protein content (5%) in the Hepatitis B vaccine from 
Smith, Kline and French (now Engerix B from Glaxo Smith Kline), was a risk factor for IgE/IgG 
antibody synthesis against  Saccharomyces cerevisiae. However, Wiedermann et al. found no IgE or 
IgG synthesis in the study population and concluded that the yeast content in the vaccine was safe. 
Reviewing the details of their study suggests that this matter needs to be revisited.
Wiedermann et al. studied only 50 healthy adult subjects. Engerix B today is administered to millions 
of babies, the day they are born. The subjects in the study who were born at least 50 years ago, were 
less atopic than children born now.8 The adult subjects in the study having been exposed to yeast via 
the oral route, throughout their lifetime, would have developed immune tolerance to it.9 This may 
explain their unresponsiveness to injected yeast antigen. Newborns of course have had very little 
exposure to yeast prior to the Hepatitis B vaccine they receive at birth. Not all study subjects received 
the full dose of hepatitis B surface antigen (HbsAg) of 20 mcg (and proportional quantity of yeast 
contaminants). Adult subjects likely weighed on average about 150 lb., compared to about 7 lb. for 
newborns. Recommended adult dosage is 20 mcg and pediatric dose is 10 mcg HbsAg. With a ~20x 
body weight difference and only a 2x antigen dosage difference, one can expect pediatric vaccine 
recipients to have significantly longer immune system exposure to both HbsAg and the yeast 
contaminants. Thus increasing the risk of inducing IgE/IgG antibodies to yeast.
Many studies on vaccine adverse events focus only on the “active ingredients”.10,11 For example, 
Hepatitis B vaccines Recombivax HB6 and Engerix B4 are considered equivalent. However, Engerix B 
can have 5X the amount of yeast proteins as Recombivax HB! So, the results of studies that only focus 
on the “active ingredients” can be misleading if the adverse event is caused by the excipients or 
contaminants in the vaccine.
Sensitization to yeast proteins in vaccines may thus explain the epidemic of atopic dermatitis in 
children today.
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